This initiative establishes expert-defined terms for measuring disease activity in atopic dermatitis, suggesting a unified approach for treatment evaluation.
This modified Delphi initiative establishes a globally endorsed, expert-derived framework defining LDA, vLDA, on-drug complete control, and off-drug remission in AD. These standardized, clinically meaningful definitions provide a foundation for harmonized trial design, regulatory evaluation, and longitudinal comparative effectiveness research. By promoting consistent assessment of disease control across studies, this framework advances the field toward evidence-based, treat-to-target AD strategies.
No takes yet. Share an insight, caveat, or question.
Merola et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: